Finally, given that combination therapy caused decreased cyclin B1 expression in AI-resistant cells, this may represent a unique opportunity to expand the repertoire of cell cycle inhibitors that can be purposed for endocrine resistant HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.